← Back to Clinical Trials
Recruiting NCT03822741

NCT03822741 Etiology and Treatment of Neonatal Seizure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03822741
Status Recruiting
Phase
Sponsor Children's Hospital of Fudan University
Condition Seizures
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2016-08-08
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 12 Months
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2016-08-08 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Genetic diagnosis for neonates suffering from epilepsy has important implications for treatment, prognosis, and development of precision medicine strategies. Investigator performed exome sequencing (ES) or targeted sequencing on neonates with seizure onset within the first month of life. Investigator subgrouped our patients based on the onset age of seizure into neonatal and before 1 year (1-12 months), to compare the clinical and genetic features and treatment strategies.

Eligibility Criteria

Inclusion Criteria: * severe seizures in neonates or generalized epilepsy or intractable epilepsy in infancy with generalized tonic-clonic seizures, * seizures onset before 1 year of age, * epileptic syndromes/epileptic-encephalopathies with unknown etiology. Exclusion Criteria: * Patients were excluded if they had traumas, central nervous system infections, hypoxic-ischemic encephalopathy, vascular events, systemic infections, and diagnosed metabolic disorders, and pathogenic copy-number variants were identified using array-based comparative genomic hybridization (CGH).

Contact & Investigator

Central Contact

Wenhao Zhou, Doctor

✉ zwhchfu@126.com
Principal Investigator

Wenhao Zhou, Doctor

STUDY CHAIR

Children's Hospital of Fudan University

Frequently Asked Questions

Who can join the NCT03822741 clinical trial?

This trial is open to participants of all sexes, up to 12 Months, studying Seizures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03822741 currently recruiting?

Yes, NCT03822741 is actively recruiting participants. Contact the research team at zwhchfu@126.com for enrollment information.

Where is the NCT03822741 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT03822741 clinical trial?

NCT03822741 is sponsored by Children's Hospital of Fudan University. The principal investigator is Wenhao Zhou, Doctor at Children's Hospital of Fudan University. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology